Last update 20 Mar 2025

Zongertinib

Overview

Basic Info

Drug Type
Small molecule drug
Synonyms
佐博替尼
Target
Action
antagonists
Mechanism
HER2 antagonists(Receptor protein-tyrosine kinase erbB-2 antagonists)
Inactive Indication-
Inactive Organization-
Drug Highest PhaseNDA/BLA
First Approval Date-
RegulationFast Track (United States), Breakthrough Therapy (United States), Priority Review (United States)
Login to view timeline

Structure/Sequence

Molecular FormulaC29H29N9O2
InChIKeyYSGNGFPNTLERCR-UHFFFAOYSA-N
CAS Registry2728667-27-2

R&D Status

10 top R&D records.
Login
to view more data
IndicationHighest PhaseCountry/LocationOrganizationDate
HER2 mutant non-small cell lung cancerNDA/BLA
China
15 Jan 2025
Adenocarcinoma of EsophagusPhase 2
Italy
28 Jun 2024
Adenocarcinoma of EsophagusPhase 2
Japan
28 Jun 2024
Adenocarcinoma of EsophagusPhase 2
Belgium
28 Jun 2024
Adenocarcinoma of EsophagusPhase 2
United States
28 Jun 2024
HER2 Positive Adenocarcinoma of EsophagusPhase 2
Japan
28 Jun 2024
HER2 Positive Adenocarcinoma of EsophagusPhase 2
Belgium
28 Jun 2024
HER2 Positive Adenocarcinoma of EsophagusPhase 2
United States
28 Jun 2024
HER2 Positive Adenocarcinoma of EsophagusPhase 2
Italy
28 Jun 2024
HER2 Positive Adenocarcinoma of EsophagusPhase 2
Spain
28 Jun 2024
Login to view more data

Clinical Result

Indication
Phase
Evaluation
View All Results
Study
Phase
PopulationAnalyzed EnrollmentGroupResultsEvaluationPublication Date
Phase 1
-
(每日120毫克,单次服用)
(dylcltrtai) = qpxmmpzwnq ewzpnizybo (vynalezuwz )
Positive
10 Dec 2024
Phase 1
105
(hkcdzdrrfp) = MTD was not reached for BID or QD schedules. wyjlykdtye (dhoqxnqoej )
Positive
07 Dec 2024
(Asian pts)
Phase 1
83
(ttczyxhjxl) = uhyjczhaai lllbfsfveq (hhamglqjim )
Positive
10 Sep 2024
(lqrunrroko) = okculwsjlf fvrberkffi (qyfhlbpkkj )
Phase 1
61
Zongertinib 15/30/60/100/150 mg BID
(syuedzalwx) = psamgojonk kqoygwbxqr (hdfcnikipg )
Positive
24 May 2024
Zongertinib 60/120/180/240/300/360 mg QD
(syuedzalwx) = klgonpmvih kqoygwbxqr (hdfcnikipg )
Phase 1
103
(dzflgyfjgf) = qlfuulvudf okftpvcwpw (hmgkqazmvy )
Positive
22 Mar 2024
(ndgpuihxrv) = xlqhcytnrj gmxsnflugt (lvvvltzncn )
Phase 1
43
(npbuygouzn) = 4 DLTs have been observed (all outside of the MTD evaluation period; grade [G] 2 edema [60 mg BID], G2 diarrhea [150 mg BID], G3 anemia [60 mg QD], G3 increased ALT [180 mg QD]). dfiwbaujeb (hrookvrjbt )
Positive
11 Sep 2023
Phase 1
34
(uvlbyssdtv) = dzqhxlwuuv rnewpatmwh (kprxmnjfri )
Positive
31 Mar 2023
(NSCLC)
(cqrwbupjmh) = ryrpgfmvql szsgomujbp (ovfpkgplcn )
Login to view more data

Translational Medicine

Boost your research with our translational medicine data.
Boost your research with our translational medicine data.

Deal

Boost your decision using our deal data.
Boost your decision using our deal data.

Core Patent

Boost your research with our Core Patent data.
Boost your research with our Core Patent data.

Clinical Trial

Identify the latest clinical trials across global registries.
Identify the latest clinical trials across global registries.

Approval

Accelerate your research with the latest regulatory approval information.
Accelerate your research with the latest regulatory approval information.

Regulation

Understand key drug designations in just a few clicks with Synapse.
Understand key drug designations in just a few clicks with Synapse.
Chat with Hiro
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.
Bio
Bio Sequences Search & Analysis
Sign up for free
Chemical
Chemical Structures Search & Analysis
Sign up for free